Abstract | BACKGROUND: OBJECTIVES: SEARCH STRATEGY: We searched the following databases: Cochrane Central Register of Controlled Trials (to Second Quarter 2009), MEDLINE (2005-June 2009), International Pharmaceutical Abstracts (1970-June 2009) and EMBASE (2007-June 2009). Bibliographic citations from retrieved studies were also reviewed. No language restrictions were applied. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and assessed trial quality using the risk of bias tool. Data synthesis and analysis was performed using RevMan 5. MAIN RESULTS: The search strategy did not yield any randomized controlled trials comparing hydralazine to placebo for inclusion in this review. There is insufficient evidence to conclude on the effects of hydralazine versus placebo on mortality, morbidity, withdrawals due to adverse effects, serious adverse events, or systolic and diastolic blood pressure. Some of the adverse effects related to hydralazine that have been reported in the literature include reflex tachycardia, hemolytic anemia, vasculitis, glomerulonephritis, and a lupus-like syndrome. AUTHORS' CONCLUSIONS:
Hydralazine may reduce blood pressure when compared to placebo in patients with primary hypertension, however this data is based on before and after studies, not RCTs. Furthermore, its effect on clinical outcomes remains uncertain.
|
Authors | Michael R Kandler, Greg T Mah, Aaron M Tejani, Sarah N Stabler |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 8
Pg. CD004934
(Aug 04 2010)
ISSN: 1469-493X [Electronic] England |
PMID | 20687078
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Antihypertensive Agents
- Vasodilator Agents
- Hydralazine
|
Topics |
- Administration, Oral
- Antihypertensive Agents
(therapeutic use)
- Humans
- Hydralazine
(therapeutic use)
- Hypertension
(drug therapy)
- Vasodilator Agents
(therapeutic use)
|